The insulin market in MEA is expected to grow from US$ 3,255.91 million in 2022 to US$ 5,549.57 million by 2028. It is estimated to grow at a CAGR of 9.2% from 2022 to 2028.

Insufficient Competition from Biosimilars to Provide Opportunities in Market

The dominance of major players in the Middle East & Africa has led to an increase in the insulin market value. Novo Nordisk A/S, Elli Lily and Company, and Sanofi have a cumulative market revenue of over 90%. This is majorly credited to the evergreening of patents currently held by these dominating players. Moreover, patients’ lack of trust in biosimilar drugs is a significant factor augmenting the insulin market growth. According to a study conducted by Health Action International (2019), states that Eli Lilly and Company, Novo Nordisk, and Sanofi are the only three manufacturers of insulin, and they generate ~90% of revenue in the market.

Market Overview

The insulin market in the Middle East & Africa is segmented into Saudi Arabia, the UAE, South Africa, and the Rest of MEA. The region is expected to present notable growth opportunities to market players owing to the rise in the prevalence of diabetes, surge in healthcare expenditure, increasing awareness about diabetes, and preventive measures being taken to control the incidences of diabetes. In Saudi Arabia, diabetes affects ~20% of the population. The disease accounts for one-fourth of the total healthcare expenditure in the country. Diabetes mellitus is the prevalent form of diabetes in the country. According to International Diabetes Federation, in 2019, ~7 million people in Saudi Arabia had diabetes. The country ranks eighth in terms of the prevalence of diabetes, including children and adults living with type 1 diabetes mellitus. It is the 4th country in the world in terms of the incidence rate, as ~33.5 per 1 million people are affected by type 1 diabetes mellitus.

MEA Insulin Market Revenue and Forecast to 2028 (US$ Million)

MEA Insulin Market Segmentation

The MEA insulin market is segmented into type and country. Based on type, the market is segmented into long acting insulin, rapid acting insulin, short acting insulin & traditional human insulin, concentrated insulin & combination insulin, biosimilar insulin, glucagon-like peptide-1 (GLP-1), pen & needle, and others. The long acting insulin segment registered the largest market share in 2022.

Based on long acting insulin, the MEA insulin market is sub-segmented into Levemir, lantus, basaglar, and tresiba. The tresiba segment registered the largest market share in 2022.

Based on short acting insulin and traditional human insulin, the MEA insulin market is sub-segmented into Novolin R, Humalin R, Insuman, others. The insuman segment held the largest market share in 2022.

Based on concentrated insulin and combination insulin, the MEA insulin market is sub-segmented into novomix, ryzodeg, xultophy, and soliqua/suliqua. The xultophy segment held the largest market share in 2022.

Based on biosimilar insulin, the MEA insulin market is sub-segmented into insulin glargine biosimilars and human insulin biosimilars. The insulin glargine biosimilars segment held the largest market share in 2022.

Based on country, the market is segmented into Saudi Arabia, South Africa, UAE, and Rest of MEA. Saudi Arabia dominated the market share in 2022.

Biocon; Eli Lilly and Company; GlaxoSmithKline plc.; Merck & Co., Inc.; Novo Nordisk A/S; Pfizer Inc.; Sanofi; Tonghua Dongbao Pharmaceutical Co., Ltd.; and Wockhardt are the leading companies operating in the insulin market in the region.

TABLE OF CONTENTS

1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 MEA Insulin Market – By Type
1.3.2 MEA Insulin Market – By Country
2. MEA Insulin Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. MEA Insulin Market – Market Landscape
4.1 Overview
4.2 MEA PEST Analysis
4.2.1 Expert Opinion
5. MEA Insulin Market– Key Market Dynamics
5.1 Market Drivers
5.1.1 Increase in Incidence of Diabetes
5.1.2 Rapid Technological Developments in Insulin Delivery Devices by Major Players
5.2 Market Restraints
5.2.1 Risks Associated with Insulin Delivery Devices
5.3 Market Opportunities
5.3.1 Insufficient Competition from Biosimilars
5.4 Future Trends
5.4.1 Regeneration of Diabetic Pancreas with Advanced Transplants
5.5 Impact Analysis
6. Insulin Market– MEA Analysis
6.1 MEA Insulin Market Revenue Forecast and Analysis
7. MEA Insulin Market Analysis – By Type
7.1 Overview
7.2 MEA Insulin Market Revenue Share, by Type (2021 and 2028)
7.3 Long Acting Insulin
7.3.1 Overview
7.3.2 Long Acting Insulin: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.1 Levemir
7.3.2.1.1 Overview
7.3.2.1.2 Levemir: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.2 Lantus
7.3.2.2.1 Overview
7.3.2.2.2 Lantus: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.3 Basaglar
7.3.2.3.1 Overview
7.3.2.3.2 Basaglar: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.3.2.4 Tresiba
7.3.2.4.1 Overview
7.3.2.4.2 Tresiba: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Rapid Acting Insulins
7.4.1 Overview
7.4.2 Rapid Acting Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.1 Novolog
7.4.2.1.1 Overview
7.4.2.1.2 Novolog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.2 Humalog
7.4.2.2.1 Overview
7.4.2.2.2 Humalog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.3 Admelog
7.4.2.3.1 Overview
7.4.2.3.2 Admelog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.4.2.4 Others
7.4.2.4.1 Overview
7.4.2.4.2 Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Short Acting Insulins and Traditional Human Insulins
7.5.1 Overview
7.5.2 Short Acting Insulins and Traditional Human Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.1 Novolin R
7.5.2.1.1 Overview
7.5.2.1.2 Novolin R: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.2 Humulin R
7.5.2.2.1 Overview
7.5.2.2.2 Humulin R: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.3 Insuman
7.5.2.3.1 Overview
7.5.2.3.2 Insuman: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.5.2.4 Others
7.5.2.4.1 Overview
7.5.2.4.2 Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6 Concentrated Insulins and Combination Insulins
7.6.1 Overview
7.6.2 Concentrated Insulins and Combination Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.1 NovoMix
7.6.2.1.1 Overview
7.6.2.1.2 NovoMix: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.2 Ryzodeg
7.6.2.2.1 Overview
7.6.2.2.2 Ryzodeg: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.3 Xultophy
7.6.2.3.1 Overview
7.6.2.3.2 Xultophy: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.6.2.4 Soliqua/Suliqua
7.6.2.4.1 Overview
7.6.2.4.2 Soliqua/Suliqua: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.7 Biosimilar Insulins
7.7.1 Overview
7.7.2 Biosimilar Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.7.2.1 Insulin Glargine
7.7.2.1.1 Overview
7.7.2.1.2 Insulin Glargine: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.7.2.2 Human Insulin
7.7.2.2.1 Overview
7.7.2.2.2 Human Insulin: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.8 Glucagon-like peptide-1 (GLP-1)
7.8.1 Overview
7.8.2 Glucagon-like peptide-1 (GLP-1): Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.9 Pens and Needles
7.9.1 Overview
7.9.2 Pens and Needles: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
7.10 Others
7.10.1 Overview
7.10.2 Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
8. MEA Insulin Market – Country Analysis
8.1 Overview
8.1.1 Middle East & Africa Insulin Market Revenue and Forecast to 2028, by Country (%)
8.1.1.1 UAE: Insulin Market Revenue and Forecast to 2028 (US$ Million)
8.1.1.1.1 UAE: Insulin Market Revenue and Forecast to 2028 (US$ Million)
8.1.1.1.2 UAE: Insulin Market, By Type, 2019–2028 (US$ Million)
8.1.1.1.2.1 UAE: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.1.1.1.2.2 UAE: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.1.1.1.2.3 UAE: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.1.1.1.2.4 UAE: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.1.1.1.2.5 UAE: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.1.1.2 Saudi Arabia: Insulin Market Revenue and Forecast to 2028 (US$ Million)
8.1.1.2.1 Saudi Arabia: Insulin Market Revenue and Forecast to 2028 (US$ Million)
8.1.1.2.2 Saudi Arabia: Insulin Market, By Type, 2019–2028 (US$ Million)
8.1.1.2.2.1 Saudi Arabia: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.1.1.2.2.2 Saudi Arabia: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.1.1.2.2.3 Saudi Arabia: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.1.1.2.2.4 Saudi Arabia: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.1.1.2.2.5 Saudi Arabia: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.1.1.3 South Africa: Insulin Market Revenue and Forecast to 2028 (US$ Million)
8.1.1.3.1 South Africa Insulin Market Revenue and Forecast to 2028 (US$ Million)
8.1.1.3.2 South Africa: Insulin Market, By Type, 2019–2028 (US$ Million)
8.1.1.3.2.1 South Africa: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.1.1.3.2.2 South Africa: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.1.1.3.2.3 South Africa: Insulin Market , By Short acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.1.1.3.2.4 South Africa: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.1.1.3.2.5 South Africa: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
8.1.1.4 Rest of Middle East & Africa: Insulin Market Revenue and Forecast to 2028 (US$ Million)
8.1.1.4.1 Rest of Middle East & Africa: Insulin Market Revenue and Forecast to 2028 (US$ Million)
8.1.1.4.2 Rest of Middle East & Africa: Insulin Market, By Type, 2019–2028 (US$ Million)
8.1.1.4.2.1 Rest of Middle East & Africa: Insulin Market, By Long Acting Insulin, 2019–2028 (US$ Million)
8.1.1.4.2.2 Rest of Middle East & Africa: Insulin Market, By Rapid Acting Insulin, 2019–2028 (US$ Million)
8.1.1.4.2.3 Rest of Middle East & Africa: Insulin Market, By Short acting Insulins and Traditional Human Insulins, 2019–2028 (US$ Million)
8.1.1.4.2.4 Rest of Middle East & Africa: Insulin Market, By Concentrated Insulins and Combination Insulins, 2019–2028 (US$ Million)
8.1.1.4.2.5 Rest of Middle East & Africa: Insulin Market, By Biosimilar Insulins, 2019–2028 (US$ Million)
9. MEA Insulin Market–Industry Landscape
9.1 Overview
9.2 Organic Developments
9.2.1 Overview
9.3 Inorganic Developments
9.3.1 Overview
10. Company Profile
10.1 Eli Lilly and Company
10.1.1 Key Facts
10.1.2 Business Description
10.1.3 Products and Services
10.1.4 Financial Overview
10.1.5 SWOT Analysis
10.1.6 Key Developments
10.2 Novo Nordisk A/S
10.2.1 Key Facts
10.2.2 Business Description
10.2.3 Products and Services
10.2.4 Financial Overview
10.2.5 SWOT Analysis
10.2.6 Key Developments
10.3 Biocon
10.3.1 Key Facts
10.3.2 Business Description
10.3.3 Products and Services
10.3.4 Financial Overview
10.3.5 SWOT Analysis
10.3.6 Key Developments
10.4 Wockhardt
10.4.1 Key Facts
10.4.2 Business Description
10.4.3 Products and Services
10.4.4 Financial Overview
10.4.5 SWOT Analysis
10.4.6 Key Developments
10.5 GlaxoSmithKline plc.
10.5.1 Key Facts
10.5.2 Business Description
10.5.3 Products and Services
10.5.4 Financial Overview
10.5.5 SWOT Analysis
10.5.6 Key Developments
10.6 Sanofi
10.6.1 Key Facts
10.6.2 Business Description
10.6.3 Products and Services
10.6.4 Financial Overview
10.6.5 SWOT Analysis
10.6.6 Key Developments
10.7 Pfizer Inc.
10.7.1 Key Facts
10.7.2 Business Description
10.7.3 Products and Services
10.7.4 Financial Overview
10.7.5 SWOT Analysis
10.7.6 Key Developments
10.8 Merck & Co., Inc.
10.8.1 Key Facts
10.8.2 Business Description
10.8.3 Products and Services
10.8.4 Financial Overview
10.8.5 SWOT Analysis
10.8.6 Key Developments
10.9 Tonghua Dongbao Pharmaceutical Co., Ltd.
10.9.1 Key Facts
10.9.2 Business Description
10.9.3 Products and Services
10.9.4 Financial Overview
10.9.5 SWOT Analysis
10.9.6 Key Developments
11. Appendix
11.1 About The Insight Partners
11.2 Glossary of Terms

LIST OF TABLES

Table 1. MEA Insulin Market, Revenue and Forecast, 2019–2028 (US$ Million)
Table 2. UAE: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 3. UAE: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 4. UAE: Insulin Market, By Rapid Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 5. UAE: Insulin Market, By Short acting Insulins and Traditional Human Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 6. UAE: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 7. UAE: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 8. Saudi Arabia: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 9. Saudi Arabia: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 10. Saudi Arabia: Insulin Market, By Rapid Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 11. Saudi Arabia: Insulin Market, By Short acting Insulins and Traditional Human Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 12. Saudi Arabia: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 13. Saudi Arabia: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 14. South Africa: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 15. South Africa: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 16. South Africa: Insulin Market, By Rapid Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 17. South Africa: Insulin Market , By Short acting Insulins and Traditional Human Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 18. South Africa: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 19. South Africa: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 20. Rest of Middle East & Africa: Insulin Market, By Type – Revenue and Forecast to 2028 (US$ Million)
Table 21. Rest of Middle East & Africa: Insulin Market, By Long Acting Insulin – Revenue and forecast to 2028 (US$ Million)
Table 22. Rest of Middle East & Africa: Insulin Market, By Rapid Acting Insulin – Revenue and Forecast to 2028 (US$ Million)
Table 23. Rest of Middle East & Africa: Insulin Market , By Short acting Insulins and Traditional Human Insulins – Revenue and Forecast to 2028 (US$ Million)
Table 24. Rest of Middle East & Africa: Insulin Market, By Concentrated Insulins and Combination Insulins- Revenue and Forecast to 2028  (US$ Million)
Table 25. Rest of Middle East & Africa: Insulin Market, By Biosimilar Insulins- Revenue and Forecast to 2028 (US$ Million)
Table 26. Organic Developments in the Insulin Market
Table 27. Inorganic Developments in the Insulin Market
Table 28. Glossary of Terms, MEA Insulin Market
 
 

LIST OF FIGURES

Figure 1. MEA Insulin Market Segmentation
Figure 2. MEA Insulin Market Segmentation, By Country
Figure 3. MEA Insulin Market Overview
Figure 4. The Long Acting Insulin Segment Held Largest Share of Type in the Insulin Market
Figure 5. Saudi Arabia Is Expected to Show Remarkable Growth During the Forecast Period
Figure 7. Middle East & Africa PEST Analysis
Figure 8. Expert Opinion
Figure 9. MEA Insulin Market Impact Analysis of Drivers and Restraints
Figure 10. MEA Insulin Market– Revenue Forecast and Analysis
Figure 11. MEA Insulin Market Revenue Share, by Type (2021 and 2028)
Figure 12. MEA Long Acting Insulin: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. MEA Levemir: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. MEA Lantus: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 15. MEA Basaglar: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. MEA Tresiba: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. MEA Rapid Acting Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. MEA Novolog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. MEA Humalog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 20. MEA Admelog: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. MEA Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. MEA Short Acting Insulins and Traditional Human Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. MEA Novolin R: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. MEA Humulin R: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. MEA Insuman: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. MEA Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. MEA Concentrated Insulins and Combination Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. MEA NovoMix: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 29. MEA Ryzodeg: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 30. MEA Xultophy: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. MEA Soliqua/Suliqua: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. MEA Biosimilar Insulins: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. MEA Insulin Glargine: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. MEA Human Insulin: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. MEA Glucagon-like peptide-1 (GLP-1): Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 36. MEA Pens and Needles: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 37. MEA Others: Insulin Market – Revenue and Forecast to 2028 (US$ Million)
Figure 38. Middle East & Africa Insulin Market Revenue Overview, by Country, 2021 (US$ Million)
Figure 39. Middle East & Africa Insulin Market Revenue and Forecast to 2028, by Country (%)
Figure 40. UAE: Insulin Market Revenue and Forecast to 2028 (US$ Million)
Figure 41. Saudi Arabia: Insulin Market Revenue and Forecast to 2028 (US$ Million)
Figure 42. South Africa: Insulin Market Revenue and Forecast to 2028 (US$ Million)
Figure 43. Rest of Middle East & Africa: Insulin MarketRevenue and Forecast to 2028 (US$ Million)

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the MEA insulin market.
● Highlights key business priorities in order to assist companies to realign their business strategies
● The key findings and recommendations highlight crucial progressive industry trends in the MEA insulin market, thereby allowing players across the value chain to develop effective long-term strategies
● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
● Scrutinize in-depth MEA market trends and outlook coupled with the factors driving the insulin market, as well as those hindering it
● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

The List of Companies – Middle East & Africa Insulin Market

● Biocon
● Eli Lilly and Company
● GlaxoSmithKline plc.
● Merck & Co., Inc.
● Novo Nordisk A/S
● Pfizer Inc.
● Sanofi
● Tonghua Dongbao Pharmaceutical Co., Ltd.
● Wockhardt